结论这项多国队列研究表明,在抗病毒治疗开始时HBeAg阳性似乎是一个独立因素,与非肝硬化CHB患者的肝癌风险较低相关,但在肝硬化CHB患者中则不然。文献索引:Heejoon Jang etal.Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral AntiviralTreatment in Patients with Chronic Hepatitis B.Clinical Gastroenterologyand Hepatology.